CA
NZ
UK
AU
IND
US
Nuwellis (NASDAQ:NUWE) shares fell in pre-market trading Friday even after the company announced continued commercial momentum for its Aquadex SmartFlow system, reporting 31 consoles sold year-to-date in 2026. Nuwellis is an Eden Prairie, Minnesota-based medical technology company dedicated to developing and commercializing solutions for …
Ultragenyx Pharmaceutical (NASDAQ:RARE) shares ticked higher in pre-market trading Friday, building on Thursday's sharp gain after the FDA granted full approval to FAYUVI (UX111), the company's first-ever treatment for Sanfilippo syndrome type A. Ultragenyx is a Novato, California-based commercial-stage biopharmaceutical company that identifies, develops, …
Xenon Pharmaceuticals (NASDAQ:XENE) shares plunged in pre-market trading Friday after the company disclosed a voluntary pause in new patient enrollment for its azetukalner (formerly XEN1101) studies in major depressive disorder and bipolar depression, following neuropsychiatric adverse events not previously seen in earlier trial phases. …
Zevra Therapeutics (NASDAQ:ZVRA) shares gained in pre-market trading Friday, building on investor enthusiasm following management's presentation at the H.C. Wainwright 28th Annual Global Investment Conference this week. Zevra Therapeutics, founded in 2006 as KemPharm and rebranded in February 2023, is a Boston-headquartered commercial-stage biopharmaceutical …
Aethlon Medical (NASDAQ:AEMD) shares pulled back in pre-market trading Friday, cooling off after Thursday's 374.13% single-session surge on news of a definitive merger agreement with North Immunology, a privately held biotechnology company developing bispecific antibodies for immune and inflammatory diseases. Aethlon Medical is a …
Tempest Therapeutics (Nasdaq: TPST) was the session's biggest gainer, closing up 59% at $1.20 after securing an exclusive option agreement with Senlang for a CD7-targeted lentiviral vector platform and in vivo CAR-T portfolio. The deal adds a Phase 1 BCMA/GPRC5D dual-targeting candidate for multiple …
The move extends strategic momentum from a September 9, 2026 restructuring in which PRF Technologies (Nasdaq: PRFX) established GridFeed as a dedicated corporate unit focused on forming alliances with data center operators. The initiative seeks to give operators enhanced capacity management tools, reduced electricity …
The update follows earlier positive initial efficacy data from Part C of the Phase 2 expansion trial, which evaluated ateganosine followed by cemiplimab in third-line advanced NSCLC. That cohort showed an interim disease control rate of 90.5%, data that had been noted on July …
The new collaboration sits alongside Tiziana Life Sciences' (Nasdaq: TLSA) ongoing, blinded Phase 2 trial in non-active secondary progressive multiple sclerosis, for which a data readout remains on track for October 2026. Together, the two programs broaden the company's multiple sclerosis pipeline across different …
The option agreement is designed to complement Tempest Therapeutics' (Nasdaq: TPST) own CD7-targeted lipid nanoparticle in vivo CAR-T platform, which remains in earlier-stage development. By adding a lentiviral vector approach through Senlang, the company gains a second, potentially more durable route to generating CAR-T …
Please wait processing your request...